Observational data shows increased utilization and price margins of oncology biosimilars in hospitals, indicating market trends.
Hospital price markup margins from the administration of oncology biosimilars have increased over time and have been accompanied by large increases in the utilization of these therapies.
No takes yet. Share an insight, caveat, or question.
Robinson et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: